|

GTB-5550 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Camelid Nanobody B7-H3 Tri-Specific Killer Engager (camB7-H3 TriKE®)

Pipeline

Phase 1: 1

Top Sponsors

  • Masonic Cancer Center, University of Minnesota1

Indications

  • Tri-specific Killer Engager1
  • Advanced Solid Tumor1
  • Solid Tumor1
  • Cancer1

Minneapolis, Minnesota1 trial

GTB-5550 in Advanced Solid Tumors

Masonic Cancer Center at University of Minnesota

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.